Expert Interview
Discussing the Current Usage of Apellis Pharmaceuticals' SYFOVRE® (pegcetacoplan), a Complement C3 Inhibitor for Geographic Atrophy
Ticker(s): APLS, BIIBInstitution: Cumberland Valley Retina Consultants
- Board-Certified Ophthalmologist and Retina Specialist with fellowship training in Medical Retina
- Currently manages 800 patients with geographic atrophy and 200 patients monthly with diabetic retinopathy. Specializes in evaluating and treating all disorders of the retina and macula including uveitis and innovative treatments for AMD and diabetic retinopathy
- Specializes in diseases of the retina and macula including age-related macular degeneration, diabetic retinopathy, retinal vascular disorders, and uveitis; actively involved in clinical research and participation in retina clinical trials, with peer-reviewed publications and presentations at international ophthalmology meetings, contributing to advancing therapeutic approaches in retinal disease
How many patients do you manage with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), rate your experience with syfovre
Added By: lilly_adminWhat % of your GA patients are eligible for injections?
Added By: ben_adminHow do you decide between Syfovre and Izervay? Do you have a preference?
Added By: ben_adminDo you expect your usage of Syfovre to increase, decrease or stay the same in the next few years?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Apr 13, 2026
- Call Time
- 04:30 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
